Molecular Profile Detail

Profile Name BRCA2 wild-type
Gene Variant Detail

BRCA2 wild-type (no effect)

Relevant Treatment Approaches


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRCA2 wild-type colorectal adenocarcinoma sensitive AZD6738 + Radiotherapy Preclinical - Cell culture Actionable In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line harboring wild-type BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704). 28062704
Clinical Trial Phase Therapies Title Recruitment Status
NCT02498613 Phase II Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02983799 Phase II Olaparib Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Active, not recruiting